Noteworthy, FLT3i quizartinib and JAK1/2i ruxolitinib enhanced the effect of the combinations of Polθi + ALDHi and Polθi + ADH5i in AML and MPN patient cells. Here, ALDH2 is linked to acute myeloid leukemia.